<DOC>
	<DOC>NCT00568984</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes</brief_summary>
	<brief_title>Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes for at least 3 months No previous treatment for diabetes HbA1c between 7.012.0% Body Mass Index (BMI) between 19.040.0 kg/m2 Type 1 diabetes Known unstable/untreated proliferative retinopathy Uncontrolled treated/untreated hypertension Pregnancy, breastfeeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>